Blog
RSS FeedPosted by Michael Wonder on 30 Jan 2023
Life sciences industry calls for better funding for medicine and technology regulator
31 January 2023 - The life sciences, health and medicine sectors have come together to call for improved funding of ...
Posted by Michael Wonder on 30 Jan 2023
Achieving patient centeredness in Medicare’s new drug price negotiation program
27 January 2023 - The Inflation Reduction Act mandated the creation of a Drug Price Negotiation Program focused on developing a ...
Posted by Michael Wonder on 26 Jan 2023
Big pharma groups rejoin battle with governments on drug prices
24 January 2023 - Tight budgets and US reforms are ending a truce between the industry and health authorities. ...
Posted by Michael Wonder on 26 Jan 2023
Update on US FDA emergency use authorisation of Evusheld
26 January 2023 - The US FDA has stated that AstraZeneca’s Evusheld (tixagevimab and cilgavimab) is not currently authorised for ...
Posted by Michael Wonder on 26 Jan 2023
Patent reform and lower drug prices should be bipartisan priorities
25 January 2023 - As the 118th Congress convenes this month in Washington D.C., many pundits and advocates have little ...
Posted by Michael Wonder on 26 Jan 2023
A “method of use” to prevent generic and biosimilar market entry
25 January 2023 - A critical pathway that generics and biosimilars manufacturers have used to circumvent patent thickets has been “skinny ...
Posted by Michael Wonder on 25 Jan 2023
Pricing of medicines in Switzerland | Three yearly price review: What are the most important changes for 2023?
24 January 2023 - The Federal Office of Public Health reviews the price of every medicinal product that is reimbursed under ...
Posted by Michael Wonder on 24 Jan 2023
The FDA’s power to approve drugs faces sweeping challenge in lawsuit seeking to pull abortion pill from US market
24 January 2023 - Anti-abortion physicians are suing to overturn the FDA’s approval of mifepristone, which dates back more than two ...
Posted by Michael Wonder on 23 Jan 2023
Despite court ruling, FDA will continue with its approach to approving orphan drug exclusivity
23 January 2023 - In an unexpected move, the FDA will continue to apply exclusive marketing rights for so called ...
Posted by Michael Wonder on 23 Jan 2023
TGA commences evaluation of Moderna COVID-19 vaccine (Spikevax) for potential transition to full registration
20 January 2023 - The TGA has commenced evaluation of an application from Moderna to transition its COVID-19 vaccine, Spikevax, ...
Posted by Michael Wonder on 21 Jan 2023
Novartis warns US plan to curb drug prices could hit key research
21 January 2023 - US Government plans to rein in drug prices could discourage work in some of Novartis' most ...
Posted by Michael Wonder on 20 Jan 2023
UK's voluntary scheme for branded medicines, pricing and access (VPAS) faces a potential crisis
19 January 2023 - The UK has a “voluntary scheme for branded medicines, pricing, and access” or VPAS, which sets a ...
Posted by Michael Wonder on 18 Jan 2023
FDA’s breakthrough program: faster drug OKs without sacrificing safety
18 January 2023 - A FDA program markedly cut the time and cost of bringing to market new drugs, without ...
Posted by Michael Wonder on 18 Jan 2023
Medunik Canada obtains new Notice of Compliance from Health Canada for Ruzurgi (amifampridine) following a favourable Canadian Federal Court of Appeal ruling
17 January 2023 - Medunik Canada is pleased to announce that on 9 January 2023, the Federal Court of Appeal of ...
Posted by Michael Wonder on 16 Jan 2023
A new US law aims to reduce drug prices. But first, it might raise them.
14 January 2023 - A new US law meant to blunt drug prices could reduce pharmaceutical-company revenue by about $40 billion ...